|Videos|October 19, 2022
Bispecific Antibodies in the Treatment of R/R MM
An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
3
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5